Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.-Reference-Cited by-同舟云学术

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:LBA2-LBA2
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sweeney Christopher¹,Chen Yu-Hui¹,Carducci Michael Anthony²,Liu Glenn³,Jarrard David Frasier³,Eisenberger Mario A.²,Wong Yu-Ning⁴,Hahn Noah M.⁵,Kohli Manish⁶,Vogelzang Nicholas J.⁷,Cooney Matthew M.⁸,Dreicer Robert⁹,Picus Joel¹⁰,Shevrin Daniel H.¹¹,Hussain Maha¹²,Garcia Jorge A.⁹,DiPaola Robert S.¹³

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA

2. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

3. University of Wisconsin Carbone Cancer Center, Madison, WI

4. Fox Chase Cancer Center, Philadelphia, PA

5. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

6. Mayo Clinic, Rochester, MN

7. Comprehensive Cancer Centers of Nevada, Las Vegas, NV

8. University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

9. Cleveland Clinic, Cleveland, OH

10. Division of Oncology, Washington University in St. Louis, St. Louis, MO

11. NorthShore University HealthSystem, Evanston, IL